12-13-20 Bahraini government has registered a COVID19 vaccine developed by Chinese producer CNBG after reviewing its phase 3 clinical trial data that shows 86% efficacy rate, and 100% efficacy in preventing medium and severe symptoms.
CNBG, a subsidiary of Sinopharm, said Sat that it expects to produce 1 billion doses of COVID19 vaccine next year. So far, it has carried out phase III clinical trials in 10 countries and regions worldwide on 60,000 subjects.
